Vulvovaginal Atrophy (VVA) is a serious medical condition that affects over 32 million postmenopausal women in the US. Only 7% of those suffering are being treated due to limitations of currently available products.
More than 3.5 million breast cancer survivors have no safe therapy available.
Many women attribute VVA menopause symptoms to an unavoidable natural aging process that they need to just “live with”. They are uncomfortable discussing these symptoms and are not active in seeking help.
Our mission is to empower women to joyfully and courageously embrace their biological changes by providing a safe and effective treatment for VVA.
VVA: A Chronic and Progressive Medical Condition
During menopause the absence of estrogen causes the thinning and inflammation of the vaginal walls and lower urinary tract leading to uncomfortable symptoms. Recent research shows that over 80% of postmenopausal women experienced one or more of these symptoms.
Vaginal Irritation
and Dryness
Dyspareunia
(painful intercourse)
Recurrent Urinary Tract Infections
Significant Untapped Market Potential
Over 20 million postmenopausal women experiencing VVA symptoms are not being treated and there are currently no satisfactory options available, especially for women with breast concerns. This represents a significant US market opportunity of over $25B.
Current Treatments Fall Short
The underlying fear of estrogen limits the number of women who are willing to seek treatment for their symptoms. No currently available product meets patient and physician needs.
Systemic
Treatments
- Estrogen Replacement: Carries risks and is out of favor since release of Women’s Health Initiative (WHI) Study in 2002.
- Osphena: Non-estrogen systemic treatment for local condition not desirable.
Low Dose Intra-Vaginal
Estrogen Therapy
- Percent of market: 7%
- Fear of estrogen limits usage
- Low patient/doctor acceptance
- Intrarosa is a steroid prasterone which increases blood levels of estrogen
Over-the-Counter Lubricants/Creams
- Percent of market: 29%
- Minimal symptom relief
- Does not treat underlying condition
Addressing the Unmet Needs of Women with Breast Concerns
"That is exactly the unmet need -- one of the major groups -- women with history of breast cancer, pre-invasive disease of the breast, women with fear of breast cancer, women who don't want to use an estrogen..."
Dr. Steven R. Goldstein
Chairman, Azure Clinical Advisory Board
Professor, Obstetrics & Gynecology, New York University
Past President, North American Menopause Society